Therapeutic effect of harnal and proscar in treating benign prostatic hyperplasia.
- Author:
Zheng-yan TANG
1
;
Ke-liang PENG
;
Jian DING
;
Xiong-bing ZU
;
Lin QI
Author Information
1. Department of Urology, Xiangya Hospital, Central South University, Changsha 410008, China. xytzyan@163.com
- Publication Type:Journal Article
- MeSH:
5-alpha Reductase Inhibitors;
Adrenergic alpha-Antagonists;
therapeutic use;
Aged;
Finasteride;
therapeutic use;
Humans;
Male;
Middle Aged;
Prostatic Hyperplasia;
complications;
drug therapy;
Urination Disorders;
etiology;
physiopathology;
Urodynamics
- From:
Journal of Central South University(Medical Sciences)
2005;30(6):708-710
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the therapeutic effect of harnal and proscar in treating benign prostatic hyperplasia (BPH).
METHODS:Two hundreds and twenty-two patients with BPH were randomly assigned into 2 groups:harnal (0.2 mg/d) group (n = 112) and proscar (5 mg/d) group (n = 108). American Urologic Association Symptom Index (AUA-SI) scores, the maximal urinary flow rate (Qmax) and prostatic volume were analyzed in the 2 groups.
RESULTS:After 12 weeks of treatment, 54.5% of the harnal group improved in AUA-SI score; 54.6% of the proscar group improved in AUA-SI score; and there was no significant difference between the 2 groups (P > 0.05). After 24 weeks of treatment, the proscar group (79.6%) had a greater improvement in AUA-SI score than the harnal group (64.3%) (P < 0.05); Qmax in the 2 groups was significantly increased than that before the treatment, and it is proportional to the therapeutic time. The prostatic volume in 2 groups had no significant change.
CONCLUSION:Harnal and proscar can significantly improve BPH symptoms and the urinary flow rate. The therapeutic effect of harnal and proscar has their own characteristics.
